Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Wednesday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a neutral rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Friday, March 15th.

Cytosorbents Trading Down 6.5 %

Shares of CTSO opened at $0.82 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.77 and a quick ratio of 1.51. The firm has a 50 day simple moving average of $0.94 and a 200-day simple moving average of $1.17. Cytosorbents has a 1-year low of $0.78 and a 1-year high of $4.29. The stock has a market cap of $44.63 million, a price-to-earnings ratio of -1.28 and a beta of 0.58.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, March 14th. The medical research company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. The business had revenue of $8.67 million during the quarter, compared to analysts’ expectations of $9.29 million. Equities analysts forecast that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CTSO. Chicago Partners Investment Group LLC raised its holdings in Cytosorbents by 84.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 16,598 shares during the last quarter. Skylands Capital LLC raised its holdings in Cytosorbents by 5.4% in the 3rd quarter. Skylands Capital LLC now owns 2,944,670 shares of the medical research company’s stock valued at $5,536,000 after acquiring an additional 151,200 shares during the last quarter. Raymond James & Associates acquired a new position in Cytosorbents in the 4th quarter valued at $56,000. Sargent Investment Group LLC raised its holdings in Cytosorbents by 4.1% in the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after acquiring an additional 51,699 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its holdings in Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 299,103 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.